Blockbuster Drugs Market

Top Selling Biologics Market, 2021-2030: Focus on Product Landscape Assessment, Ongoing Clinical Trials, Promotional Content Analysis, Other Life Cycle Management Strategies, Competition from Biosimilars, Annual Treatment Cost Comparison, Sales Evolution and Future Opportunity

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    29

  • Pages
    242

  • View Count
    19629

Blockbuster Drugs Market Overview

The blockbuster drugs market was worth around $75 billion in 2020. Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. However, owing to concerns, such as off target toxicity and low specificity, associated with chemical moieties, and the need to shift from the one-size-fits-all approach to personalized medicine, a better class of pharmacological interventions was required. The first biologic, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Briefly, biologics offer several benefits, including target specificity, better therapeutic efficacy and, consequently, favorable safety profiles compared to conventional chemical-based drugs. Moreover, these molecules have also demonstrated the ability to access elusive biological targets and treat diseases that were previously considered undruggable.

Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interventions were approved for the treatment of various disease indications in the US and Europe. Given the advantages they offer, biologics are in high demand for the treatment of different disease indications. It is a well-known fact that antibodies emerged as the major therapeutic breakthroughs and have seen significant success in the past two decades. There are other vast opportunities for biologics in the foreseeable future. This segment of healthcare industry is in the midst of numerous innovations; examples include antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapeutics, and cell and gene therapies. These developments have set the stage for significant disruption, creating more therapeutic targets and, ultimately, taking personalized healthcare to new and astounding heights.

This image highlights the context of Top Selling Biologics Market report. Biologics represent the cutting edge of medical research, offering hope to patients with clinical conditions that were previously considered incurable; 6 of the top 10 best selling drugs are biotherapeutics This image provides list of Top Selling Biologics. The biologics market is presently characterized by a number of blockbuster drugs; in fact, in 2020, a little over 65 such products were responsible for total sales worth over USD 185 billion This image presents current market landscape of Top Selling Biologics Developers. A relatively larger proportion of the top selling biologics in the market belong to big pharmaceutical companies, many of which have developed and launched multiple such products over the past few years

Despite their complex and cost intensive manufacturing protocols, biopharmaceuticals (once approved) are highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion in a year); prominent examples include (as per decreasing revenues generated in 2020) Humira®, Keytruda®, Stelara®, Opdivo®, Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®. The aforementioned products together, generated sales worth close to USD 80 billion in 2020 alone. Although the patents protecting some of these blockbuster drugs have already expired, the sales of the original product have not been significantly impacted. For instances, there are multiple approved biosimilar versions of Abbvie’s Humira®, but the company reported annual global revenues worth around USD 19 billion from the sales of this drug alone. For several other top selling biologic drugs, patents covering the affiliated intellectual property are soon expected to expire, opening the market to competition from follow-on biologics.

However, there are ways in which innovators can extend their marketing exclusivity, and delay the entry of biosimilars; popular product lifecycle management strategies include gaining marketing authorization (and exclusivity) in a new geography, proving therapeutic benefit for a different disease indication (than the one the product was originally cleared to treat), developing a new formulation of the drug, demonstrating therapeutic benefit in combination with another drug / therapy, and making the product available in a novel drug delivery device / system. In other words, companies that have developed blockbuster biologic products are expected to continue benefiting from their respective high-value assets in the short-mid term. However, we anticipate the market growth for such products to grow steadily and then plateau, before gradually declining over time, as impending patent expiries (including those that have been extended) pave way for biosimilars.

Scope of the Report

The “Blockbuster Drugs Market, 2021-2030: Focus on Product Landscape Assessment, Ongoing Clinical Trials, Promotional Content Analysis, Other Life Cycle Management Strategies, Competition from Biosimilars, Annual Treatment Cost Comparison, Sales Evolution and Future Opportunity” market report features an extensive study of the current market landscape, market size, market share, market trends, market forecast, market outlook and future opportunities of the blockbuster drugs market. The market research report includes an in-depth analysis, highlighting the key initiatives undertaken by various stakeholders engaged in blockbuster drugs market.

This image presents current market landscape of Top Selling Biologics. More than half of the best-seller biologics are monoclonal antibodies; most such drugs are designed for subcutaneous administration and largely made available in vials and prefilled syringes This image presents current market landscape of Top Selling Biologics. The popularity of the subcutaneous route is attributed to the relative ease of administration (enabling patients to self medicate), and for prolonged therapeutic action This image provides information on the annual treatment cost Top Selling Biologics. Treatment cost of biologics is a major impediment to adoption; however, developers have undertaken multiple initiatives, focused on gaining insurance coverage and offering financial assistance, to overcome this concern

Amongst other elements, the market research report features:

  • A detailed assessment of the current market landscape of top selling biologics, along with information on developers (such as year of establishment, company size, location of headquarters and current portfolio of top selling biologics), type of biologic, route of administration, target gene / antigen, type of packaging format, disease indication and target therapeutic area. 
  • It also provides an in-depth analysis of key therapeutic areas, such as oncological disorders, metabolic disorders, autoimmune disorders, gastrointestinal disorders, ophthalmic disorders, CNS/ Neurological disorders, cardiovascular disorders, blood disorders, respiratory disorders, bone disorders and others, in companies that are engaged in the development of top selling biologics.  
  • A detailed analysis of revenues generated by top selling biologics (60+) between 2016 and 2020. It includes information on reasons for significant increase / decrease in their sales in the given time span. It also includes the analysis of revenues generated by top selling biologics in 2020, based on several relevant parameters, such as type of biologic and developer. 
  • An analysis of the completed, ongoing and planned clinical studies for top selling biologics. The trials considered in the analysis were analyzed based on several relevant parameters, such as trial registration year, trial recruitment status, enrolled patient population, study design, target therapeutic area, geographical location of trials and leading organizations. It is worth highlighting that these studies were registered to evaluate the already approved top selling biologics for potential combinations, device evaluations and comparisons. 
  • A detailed analysis on the key promotional strategies that are being / have been adopted by developers of top selling biologics. It further includes a detailed Harvey ball analysis highlighting the extent of promotional content on product websites of all biologics (60+) that fall into this criterion. Additionally, it features detailed profiles, presenting promotional strategies implemented for top 7 blockbuster biologics (in terms of revenues), along with information on their promotional content on product websites (covering key messages for patients and healthcare professionals), details of patient support programs and a brief section on DTC advertisements. 
  • A brief analysis of the product lifecycle management strategies, such as geographical expansion, approval for additional disease indications, reformulations, combination therapies, exploiting alternate routes of administration reimbursement programs and pricing strategies, that have been adopted by stakeholders engaged in the development of top selling biologics, during the period 2016-2020. The information in detail has been provided for top 10 biologics (in terms of revenues).
  • An elaborate analysis representing annual treatment cost of top selling biologics. It includes grid representations, providing information on 60+ top selling biologics, based on type of biologic.

The key objective of blockbuster drugs market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for blockbuster drugs market during the forecast period. Based on multiple parameters, such as historical sales, future competition from other biologics and biosimilars, as well as impending patent expiries, we have provided informed estimates on the financial evolution of the market for the forecast period 2020-2030. It further includes sales-based forecasts of 60+ top selling biologics.

The market report also provides details on the likely distribution of the current and forecasted opportunity across type of biologic (monoclonal antibody, hormone, enzyme, fusion protein, interferon, gene therapy and others) and key players. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

This image highlights the key promotional strategies that are being / have been adopted by developers of top selling biologics. Stakeholders are actively deploying diverse promotional strategies in order to market their respective offerings and monetize the available opportunity until loss of patent exclusivity This image describes the life cycle management strategies of Top Selling Biologics. To expand patent life, players are actively exploring and researching various life cycle management strategies to continue benefiting from their best-selling products This image provides information on the current and future market trends and potential growth of Top Selling Biologics. The future opportunity for such products is likely to be distributed across different types of biologics; for a number of these drugs, biosimilars and follow-on biologics are likely to soon compete for revenues

Key Questions Answered

  • Which biologics have achieved blockbuster status in the last 1-2 years?
  • Who are the leading players engaged in the development of top selling biologics?
  • Which key clinical conditions are presently targeted by top selling biologics?
  • What are the historical global sales of top selling biologics?
  • Which product life cycle management strategies are most commonly adopted by players to extend the life of their top selling products?
  • What is the current annual treatment cost associated with top selling biologics?
  • Which regions have emerged as key hubs for conducting clinical studies focused on top selling biologics?
  • How has the biosimilars landscape in this market evolved over the past few years?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com